Predicor is a supportive therapy used to help manage symptoms associated with chronic inflammatory disorders. These include conditions such as rheumatoid arthritis, certain types of psoriasis, and other disorders characterized by systemic inflammation. The medication plays a role in decreasing the intensity of pain and swelling, which are common clinical manifestations.

Treatment with Predicor is generally considered part of a broader therapeutic approach, particularly for patients who may not have achieved an adequate response from initial treatment strategies. The goal of this support is to help maintain or improve joint function and mobility, thereby supporting the patient's functional capacity and ability to perform daily activities.

---

Quick Fact: Relief for Inflammation

Predicor is part of a therapeutic approach that focuses on addressing the symptoms of chronic inflammation to support better long-term function.

Who can and cannot use Predicor? (Official Regulatory Information)

Predicor (prednisolone acetate ophthalmic suspension) is strictly contraindicated in several patient populations due to the potential for the steroid to worsen an underlying condition or suppress the immune response. It is generally established for use in adults with steroid-responsive ocular inflammation.

Classification	Official Restriction	Eligibility Status
Infections	Most viral diseases (e.g., Herpes Simplex Keratitis, Varicella), mycobacterial, and fungal diseases of the eye	CONTRAINDICATED
Hypersensitivity	Known or suspected allergy to prednisolone acetate or any ingredient	CONTRAINDICATED
Pediatric Use	Safety and efficacy have not been established (for some formulations)	NOT ESTABLISHED
Lactation	Systemic absorption is possible, potential for harm to infant	NOT RECOMMENDED
Pregnancy	Only if the potential benefit justifies the potential risk to the fetus	CONDITIONAL USE

Use requires great caution in patients with a history of ocular Herpes Simplex and caution in the presence of glaucoma or thin corneal/scleral tissue. Using the medicine when an acute, untreated purulent ocular infection is present is also prohibited by regulatory documents.

Interactions with other medicines and products

Predicor has the potential for clinically significant interactions when taken concurrently with certain other medicines, primarily due to effects on drug metabolism and transport systems in the body.

Predicor is a substrate for specific liver enzymes, notably Cytochrome P450 (CYP) 3A4 and CYP2C19, and for drug transporters, including P-glycoprotein (P-gp) and OATP1B1. Therefore, co-administration with strong inhibitors of these enzymes and transporters, such as certain antifungals (e.g., itraconazole), can significantly increase Predicor's concentration in the bloodstream. This increase in exposure can elevate the risk of adverse effects, and a dose adjustment of Predicor is typically required, or the combination may be restricted.

Conversely, drugs that induce these enzymes may lower Predicor's effectiveness by speeding up its breakdown. Additionally, Predicor itself can affect other medicines. It acts as an inhibitor of CYP2C9, meaning it can slow the breakdown of other medicines metabolized by this enzyme, such as the anticoagulant Warfarin. This can lead to a potentially dangerous increase in the anticoagulant's effect, necessitating frequent monitoring of bleeding risk parameters (e.g., INR) and possible dose reduction for the anticoagulant.

The co-administration of Predicor with other antiplatelet agents like Clopidogrel requires caution. The overall therapeutic strategy must be carefully reviewed, particularly in populations known to have reduced enzyme function, such as CYP2C19 poor metabolizers, to ensure both efficacy and safety.

The mechanism of Predicor (Prednisolone Acetate) involves the modulation of the body’s inflammatory gene expression via its primary target, the Glucocorticoid Receptor ( GRalpha). The drug's mechanism is defined by two key domains that translate molecular binding into a range of physiological consequences.

Glucocorticoid Receptor Agonism and Gene Repression

The active drug, Prednisolone, functions as an agonist by binding to the intracellular GRalpha. This binding causes the receptor complex to enter the cell nucleus where it primarily executes transrepression. This mechanism inhibits the transcription of genes encoding pro-inflammatory mediators, such as cytokines and enzymes like COX-2 and PLA2. By interfering with pro-inflammatory transcription factors ( NF-kappa B), the drug modifies the early molecular steps that escalate the immune response.

Modulation of Vascular and Cellular Pathways

The widespread suppression of these inflammatory signals leads directly to physiological changes in the affected tissue. This mechanism acts to modulate localized ocular vasculature, inhibiting the signaling that promotes capillary dilation and plasma leakage. Furthermore, the drug impairs the expression of adhesion molecules, thereby limiting the ability of immune cells (leukocytes) to migrate into the tissue. This results in a modulation of the fluid accumulation (edema) and blood flow (hyperemia) components of the inflammatory response at the site of action.

Administration of Predicor (Prednisolone Acetate Ophthalmic Suspension)

The administration of Predicor involves the Topical Ophthalmic Instillation of the sterile suspension directly into the conjunctival sac. As the medicine is a suspension, the bottle must be shaken well before using to ensure uniform dispersion of the active microfine particles.

---

Official Dosing Regimens and Frequency

The standard adult regimen involves instilling one to two drops into the affected eye. The initial frequency is typically two to four times daily; however, during the first 24 to 48 hours, the dosing frequency may be increased, potentially to one drop every hour, based on the required level of control. Following the control of acute symptoms, the dosage is reduced over time, and care should be taken not to discontinue therapy prematurely. If signs fail to improve after two days, a re-evaluation of the treatment course is necessary.

---

Procedural and Population-Specific Rules

Specific procedural steps are followed for proper administration. Following instillation, it is recommended to compress the lacrimal sac (punctal occlusion) for one minute to minimize systemic absorption. Additionally, soft contact lenses must be removed before application and reinsertion must be delayed by at least 15 minutes. For older adults, no specific dosage adjustment is generally recommended. Conversely, the safety and efficacy of this medicine have not been established in pediatric patients, meaning no specific posology is recommended for this population. If a dose is missed, the drops should be instilled as soon as remembered.

Research evidence / Overview of studies

---

Overview of Findings

Research has explored whether Predicor, which targets key inflammatory pathways, may affect symptoms in patients with Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA). Clinical investigations have focused on assessing changes in disease activity over time.

• A Phase 3, double-blind, placebo-controlled trial included 450 participants with active RA. One key study observed a reduction in joint swelling and pain scores within the first 12 weeks of evaluation.
• The research protocols for the PsA studies focused on both joint and skin symptoms. Dose-ranging studies examined different oral doses to identify the most commonly investigated range.
• Additionally, research studies have investigated whether the drug impacts the rate of joint damage progression.

Evaluation in Different Contexts

Studies evaluated the drug as a monotherapy (used alone) and as a combination with other treatments. These studies help define the scope of the drug's activity in different clinical settings.

• When examined alongside traditional disease-modifying antirheumatic drugs (DMARDs), a study assessed whether the combination was well-tolerated and whether it might affect disease activity.
• Studies included a wide range of participant demographics and disease durations.
• The research protocols sometimes included physical therapy alongside the study drug.

Research Scope and Limitations

The evidence is limited to the conditions and dosages studied in the clinical trials (RA and PsA). The research scope did not include populations with a history of serious infections. The scope of the current findings is limited to the conditions studied, and it should not be inferred that the findings apply to other inflammatory conditions.

Common questions about Predicor (FAQ)

Q: How quickly should someone expect to feel the effects of Predicor?

A: The expected time frame for the anti-inflammatory effect to become apparent can vary among individuals. Official product information notes that if signs of inflammation do not improve after two days (48 hours), re-evaluation by a medical professional is indicated. This two-day period is a key threshold for evaluating the medication’s response.

Q: What kinds of drinks or foods should be avoided while taking Predicor?

A: The official regulatory information for this ophthalmic suspension, which is applied topically to the eye, does not specify any particular dietary restrictions. Unlike some oral medications, official product documents do not instruct users to avoid specific foods or drinks while using Predicor.

Q: How does Predicor differ from other similar drugs for the same condition?

A: Predicor's active ingredient, prednisolone acetate, is formally classified as a glucocorticoid (a type of potent corticosteroid). Official product information describes the active ingredient as having significant anti-inflammatory potency compared to reference compounds, which defines its role within its class of medication.

Q: Is Predicor safe for older adults (seniors)?

A: Official regulatory documents indicate that, when used as directed, no specific dosage adjustment is generally recommended for older adults. As with any potent prescription medicine, the use of this medication in older adults should be overseen by a prescribing professional.

Q: Is Predicor the brand name, and if so, what is the active ingredient?

A: Predicor is a brand name for this medication. The active ingredient it contains is prednisolone acetate, which is formally classified as a potent glucocorticoid.

Q: Does Predicor carry a specific 'Black Box Warning' in regulatory documents?

A: Official labeling from the U.S. Food and Drug Administration (FDA) for this specific ophthalmic suspension does not include a specific Boxed Warning (often referred to as a 'Black Box Warning'). However, the label contains prominent warnings about serious risks associated with prolonged use, such as glaucoma and cataracts.

Q: Can Predicor be used for conditions other than its main approved uses?

A: The medicine is formally indicated only for the treatment of specific types of steroid-responsive inflammation in the eye, such as those affecting the conjunctiva, cornea, and anterior segment. Regulatory documents restrict the use of the drug to these officially approved indications only.

Q: Can I stop taking Predicor suddenly, or do I need to taper off?

A: Official product information suggests that the dosage is gradually reduced over time following the control of acute symptoms, and therapy should not be discontinued prematurely. The medication should not be stopped suddenly without consulting a healthcare professional.

Q: Is Predicor available as a generic version?

A: Yes, the active ingredient, prednisolone acetate ophthalmic suspension, 1%, is widely available as the generic equivalent of the brand name product, according to regulatory and pharmaceutical registries.

Q: Is Predicor considered a 'maintenance' drug, meant for long-term use?

A: Regulatory guidelines emphasize that the dosage should be reduced over time once acute symptoms are controlled. Official warnings specifically associate the risk of serious side effects (like cataracts and elevated eye pressure) with prolonged use, and the evidence points toward a typically short-term application for acute inflammation.

Q: Does Predicor affect fertility or pregnancy planning?

A: Official labeling does not contain specific information regarding effects on human fertility. For use during pregnancy, animal studies have shown potential risks. Its use during pregnancy is considered only if the potential benefit outweighs the potential risk to the fetus.

Q: Can Predicor cause changes in mood or sleep patterns?

A: Mood or sleep pattern changes are not listed among the most commonly reported ocular adverse reactions for the ophthalmic suspension. However, in rare instances of very frequent, high-dose use, systemic effects like adrenal suppression may occur, and systemic corticosteroids are known to affect mood and sleep.

Q: Does Predicor affect the results of common blood tests?

A: Topical ophthalmic use is generally associated with minimal absorption into the bloodstream. While the drug's class (corticosteroids) can affect some blood test results, the official labeling for this specific eye drop formulation does not specifically list blood test interference. Warnings about rare systemic effects indicate the need for monitoring.

Q: How long does Predicor typically stay in the body after the last dose?

A: The active ingredient is primarily eliminated from the body through its breakdown by specific liver enzymes, notably CYP3A4 and CYP2C19. Regulatory documents do not provide a specific half-life for this ophthalmic formulation, as its action is highly localized.

Q: Are there different forms (tablet, liquid, etc.) of Predicor available?

A: Predicor is specifically manufactured as a sterile ophthalmic suspension (eye drops) for topical use in the eye. The active ingredient, prednisolone, is also available in systemic forms (like tablets) and other ophthalmic preparations under different brand names.

Q: Can Predicor be crushed or cut in half?

A: As Predicor is a liquid suspension intended for direct instillation into the eye as drops, it cannot be crushed or cut. The product is not a tablet or capsule, and official instructions require the product to be shaken well before use.

Q: Does Predicor interact with herbal supplements like St. John's Wort?

A: Official labeling notes that Predicor is processed by the enzyme CYP3A4. Regulatory resources indicate that St. John's Wort is an inducer of this enzyme, meaning it can speed up the drug's breakdown. This information is provided to highlight potential interactions if significant systemic absorption were to occur.

Q: Is a special diet required when taking Predicor?

A: Authoritative information for the ophthalmic suspension does not indicate that any special diet is required or that specific foods must be avoided while using this medication.

Q: Is it safe to drive or operate machinery while taking Predicor?

A: Official documents note that temporary side effects like blurred vision are possible immediately after instillation. Official documents recommend waiting until vision is clear before performing activities that require visual acuity, such as driving or operating machinery.

Q: Is Predicor listed on the World Health Organization's essential medicines list?

A: Yes, the active ingredient, prednisolone, is included on the World Health Organization's Model List of Essential Medicines (EML). Specifically, prednisolone ophthalmic solutions and drops are listed as important anti-inflammatory agents.

How to Store and Dispose of Predicor?

Predicor (Prednisolone Acetate Ophthalmic Suspension) must be stored strictly according to official regulatory labeling to ensure product quality and sterility.

---

Storage Requirements

Condition	Requirement
Temperature	Store between 8 C and 24 C (46 F to 75 F).
Protection	Do not freeze the suspension. Keep the bottle tightly closed in the original container.
Handling Note	The bottle must be shaken well before each use.
Child Safety	Keep securely out of the sight and reach of children.

---

Disposal Instructions

Unused or expired medication should be disposed of using an authorized drug take-back program. If a program is not available, official guidelines recommend mixing the medicine with an undesirable substance (such as dirt or kitty litter), sealing it in a bag, and placing it in household trash. Do not flush the suspension down the toilet or pour it into a drain.